Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

BDX · Q4 2025 Earnings

Becton Dickinson

Reported October 15, 2025

30-second summary

FY2025 adjusted EPS landed at $14.40 (modestly above the $14.375 midpoint of the $14.30–$14.45 guide) and Q4 organic accelerated to 3.9%, though FY organic of 2.9% came in below the 3.0–3.5% FY guide band. The story is FY2026 — initial EPS guide of $14.75–$15.05 implies +3.5% YoY at midpoint, with low single-digit revenue growth and Q1 explicitly down low single digits. Management framed the setup as "prudent" — code for embedding no macro improvement, an accelerating ~25% vaccine decline, a 100+bps Alaris headwind, and an incremental $185M tariff hit. EPS growth ex-tariff is "high single digits" at the midpoint, which tells you the tariff drag is roughly worth a full growth tier.

Headline numbers

Revenue

Q4 FY2025

$5.89B

+8.3% YoY

Key financials

Q4 FY2025

Metric	Q4 FY2025	YoY	Q3 FY2025	QoQ
Revenue	$5.89B	+8.3%	$5.51B	+6.9%

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Organic Revenue Growth	FY 2025	3.0% to 3.5%	2.9%	-0.1pts below low end of range	Met
GAAP Revenue Growth	FY 2025	8.2% to 8.7%	8.2%	at low end of range	Met

New guidance

Metric	Period	Guide	YoY
Adjusted Diluted EPS	Q1 FY2026	$2.75 to $2.85	—
Revenue	Q1 FY2026	Expected down low single digits	—
Adjusted Operating Margin	FY 2026	Approximately 25% (consistent with FY2025)	—
Adjusted Effective Tax Rate	FY 2026	14% to 15%	—
EPS Growth Excluding Tariffs	FY 2026	High single-digit growth at midpoint	—
Currency Impact on Revenue	FY 2026	Estimated ~90 basis point tailwind	—
Revenue Growth (Portfolio Basis)	FY 2026	Low single-digit overall, with mid-single-digit growth across 90% of portfolio	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Adjusted Diluted EPS	FY 2025	$14.30 to $14.45	$14.75 to $15.05	+$0.45 to +$0.60 (midpoint +3.9%)	Raised
Adjusted Revenue Growth (FXN)	FY 2025	7.8% to 8.3%	7.7%	-0.1pts below low end of range	Lowered
Adjusted Diluted EPS Growth	FY 2025	8.8% to 10.0%	~9.4% (implied at midpoint vs FY2024 base)	raised to ~9.4% (midpoint of new $14.75–$15.05 vs FY2024 base of ~$13.57)	Raised

Other KPIs

Q4 FY2025

Segment	Q4 FY2025
Organic revenue growth (Q4)	3.9%
Currency-neutral revenue growth (Q4)	7.0%
Organic revenue growth (FY2025)	2.9%
Currency-neutral revenue growth (FY2025)	7.7%

Management tone

Q2 anchor: macro stabilizing → Q3 anchor: executing through headwinds → Q4 anchor: defensive guidance reset.

Last quarter management explicitly told investors BD Excellence and sequential improvement were large enough to outrun China and life-sciences drag. This quarter the posture flipped. The Q3 framing of sequentially improving growth through market headwinds has been replaced by a portfolio-segmentation argument that effectively concedes the headline number will look weak: "low single-digit revenue growth as our starting point for the year." The signal is that management no longer believes it can mask the 10% drag with execution in the other 90%, and would rather guide below and beat than repeat FY2025's narrow miss on organic growth (2.9% vs 3.0–3.5% guide).

The vaccine line item went from planned moderation to acute. One quarter ago vaccines were a known soft sub-segment of pharm systems. This quarter management quantified a ~25% FY2026 decline worth ~50bps of company growth, and characterized the late-Q4 demand drop as evolving "rapidly." Anchor: "While we planned for a slowdown in Q4, further reductions in demand evolved rapidly late in the quarter." That late-quarter inflection — not anticipated when FY2026 internal plans were built — is the proximate cause of why the FY2026 guide carries no macro improvement assumption.

The tariff disclosure hardened. This quarter management disclosed an incremental $185M tariff headwind, characterized as "80 basis points year-over-year headwind from tariffs," with EPS growth ex-tariff at "high single digits" — quantifying that tariffs alone account for a full tier of EPS growth. Management characterized this as "in line with what we've previously communicated," though the explicit dollarization and EPS-tier framing is a step change in how directly the drag is being communicated to investors.

Alaris flipped from growth driver to drag. Last quarter Alaris was framed as the basis for "share gains and growth opportunities" with locked-in install base. This quarter it's a "100+ basis point growth headwind in FY2026" — a deterioration in narrative that reflects the remediation cycle completing and the comparable base hardening, but is nonetheless a tonal step down.

Commercial execution language hardened from "good" to "needs re-architecting." The anchor: "You don't get to market leadership in 90% of your markets without being good commercially. But we think there's another level of world-class that we're going to be driving... re-architecting our commercial operating model, moving sales direct line into the businesses." A new CRO role, an incremental $30M sales-force investment, and a two-year $200M cost-out program were announced. The message: management feels forced to take structural action rather than executing a planned strategy, and is explicit that this is a response to "speed to optimize our performance during this time."

Recurring themes management leaned on this quarter:

Macro environment deterioration in contained areas (vaccines, China, Alaris cycling)Commercial excellence acceleration through organizational restructuring and CRO roleBD Excellence business system driving margin expansion despite low organic growth90% of portfolio performing well mid-single digits while 10% faces cyclical headwindsWaters transaction as near-term value unlock with $4B proceeds for buybacksDefensive low single-digit guidance masking underlying mid-single-digit growth in core business

Risks management surfaced:

Vaccine demand continuing to decline beyond initial expectations into FY26China volume-based procurement reaching 80% coverage impacting BD interventional segmentAlaris creating 100+ basis point growth headwind in FY26 as remediation completesTariff headwinds of 80 basis points (incremental $185M) continuing through FY26Biosciences academic and government research funding remaining subdued

Answers to last quarter's watch list

Q4 organic growth >3.5% — Q4 organic landed at 3.9%, clearing the threshold. The acceleration message was vindicated at the Q4 level, but FY2025 organic still came in at 2.9%, just below the 3.0–3.5% FY band. Status: Resolved positively

Life Sciences return to growth — Biosciences and Diagnostic Solutions combined delivered approximately flat currency-neutral growth ex-discontinued platforms in Q4; biosciences academic and government research funding was cited as remaining subdued in FY2026 commentary, and life sciences will be separated as "New BD." Status: Continue monitoring

FY2026 tariff impact — Management quantified an incremental $185M tariff headwind for FY2026 (80bps year-over-year), with EPS growth ex-tariff framed at high single digits vs. +3.5% headline at midpoint. Management characterized this as "in line with what we've previously communicated." Status: Resolved — quantified

Adjusted operating margin holding above 25% — FY2025 adjusted operating margin landed at 25.0% (record level) and FY2026 guide reaffirms ~25% "consistent with FY2025." Status: Resolved positively

Separation timeline and capital return cadence — Waters transaction confirmed as the value-unlock vehicle for the life-sciences separation, with at least half of $4B proceeds earmarked for buybacks. Management cited a "real value disconnect" and new BD trading at "about 10 times multiple" as justification for aggressive repurchase, with closing "subject to obtaining required regulatory approvals and customary closing conditions." Status: Resolved positively

What to watch into next quarter

Q1 FY2026 revenue actual vs "down low single digits" guide — a deeper-than-LSD decline (e.g. -4% or worse) would suggest the vaccine and Alaris drags are larger than the 10%-of-portfolio framing implies.

Vaccine FY2026 decline holding at ~25% — management quantified this as a 50bps growth impact; any further degradation late in FY2026 would force a mid-year guidance cut similar to the FY2025 organic miss.

Waters transaction close and $4B buyback execution pace — management's value-disconnect language is unusually direct; investors should expect aggressive repurchase activity post-close and watch for any regulatory delay.

FY2026 tariff impact holding at incremental $185M — further escalation directly compresses the high-single-digit ex-tariff EPS growth claim.

Whether the ~90% of portfolio actually grows mid-single digits — the FY2026 narrative rests entirely on this segmentation. A Q1 or Q2 print where core portfolio growth disappoints would collapse the "concentrated headwinds" thesis and force a reset to genuinely-low growth as the operating reality.

Sources

BDX Q4 FY2025 press release (filed 2025-10-15): https://www.sec.gov/Archives/edgar/data/10795/000162828025045106/ex99110152025.htm
BDX Q4 FY2025 earnings call prepared remarks and Q&A (Nov. 6, 2025).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.